​

Funding Round

Series A - Rgenta Therapeutics

Series A - Rgenta Therapeutics

Investment Firm

Overview

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.

Announced Date

Nov 29, 2022

Closed on Date

Nov 29, 2022

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

AstraZeneca

AstraZeneca

No designation

CICC

CICC

CICC is a early_stage_venture and late_stage_venture and venture firm.

Participant Investors

9

Investor Name
Participant InvestorBoehringer Ingelheim Venture Fund
Participant InvestorLilly Asia Ventures
Participant InvestorAstraZeneca
Participant InvestorMatrix Partners China
Participant InvestorVivo Capital

Round Details and Background

Rgenta Therapeutics raised $52000000 on 2022-11-29 in Series A

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.

Company Funding History

6

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
May 25, 2021
Seed Round - Rgenta Therapeutics
3-18.0M
Feb 07, 2022
Venture Round - Rgenta Therapeutics
-8.9M
Nov 29, 2022
Series A - Rgenta Therapeutics
10-52.0M
May 08, 2023
Series A - Rgenta Therapeutics
2-8.0M

Recent Activity

There is no recent news or activity for this profile.